Equity
€426,554 from €1.7m in 2023
Equity fell by 75% in 2 years.
SOPACHEM
Lifetime
20 annual accounts with figures on one time axis, 49 filings since 1977peak €1.2m (2021)
€943,412▲ 112%
lowest -€131,140 (2006)
€407,699▲ 91.3%
peak €1.7m (2023)
€426,554▼ 12.7%
€1.9m▼ 20.9%
peak 4.8 FTE (2006)
3.8 FTE▲ 153%
Board6 names since 2017
1 directorHelys Group
Owners3 names in the annual accounts
100%Helys Group
Documentsfilings and deeds
10-07-202621 days before the deadline
2025financial year
Gross margin from €444,017 to €943,412Result from €213,068 to €407,699Staff from 1.5 FTE to 3.8 FTEDividend €470,000Equity from €488,856 to €426,554Debts from €2.4m to €1.9m
Key points
from the 2025 annual accountsResult
€407,699 ▲ 91.3%
The result rose in 2025: different schema filed.
Debts
€1.9m 82% of the balance sheet
Financial debts 12%Suppliers 38%Taxes and wages 2%Other 47%
Of this, €1.6m falls due within a year.
Investments
€115,310 1.8 × depreciation
Green is investment, beige is depreciation.
Staff
5 employees on 31-12-2025
In 2025, 4 people joined and 2 left.
Filings
49 annual accounts since 1977
Four of the last ten came late. The 2023 accounts came latest: 99 days after the end of the period.
Checked score
81
Excellent
Financially stronger than 46% of micro companies in pharmaceuticals (NACE 21)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.6% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.4% across 152 companies (NACE 21, micro).
About 6 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%lowest value
01-2025: 0.9%▲ +0.6 percentage points vs 12-2024
02-2025: 0.9%● unchanged vs 01-2025
03-2025: 0.9%● unchanged vs 02-2025
04-2025: 0.9%● unchanged vs 03-2025
05-2025: 1.0%▲ +0.1 percentage points vs 04-2025
06-2025: 1.0%● unchanged vs 05-2025
07-2025: 1.1%▲ +0.1 percentage points vs 06-2025
08-2025: 1.5%▲ +0.4 percentage points vs 07-2025
09-2025: 1.9%▲ +0.4 percentage points vs 08-2025
10-2025: 3.3%▲ +1.4 percentage points vs 09-2025highest value
11-2025: 0.5%▼ -2.8 percentage points vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.5%● unchanged vs 12-2025
02-2026: 0.5%● unchanged vs 01-2026
03-2026: 0.5%● unchanged vs 02-2026
04-2026: 0.5%● unchanged vs 03-2026
05-2026: 0.6%▲ +0.1 percentage points vs 04-2026
06-2026: 0.7%▲ +0.1 percentage points vs 05-2026
07-2026: 0.8%▲ +0.1 percentage points vs 06-2026
08-2026: 0.6%▼ -0.2 percentage points vs 07-2026
09-2026: 0.6%● unchanged vs 08-2026
10-2026: 0.6%● unchanged vs 09-2026
11-2026: 0.6%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
1 change of registered office in 24 months
Equity €426,554 (18.4% of total assets)
2 of the last 3 accounts late
lowers risk
Founded in 1970
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 42% of them on solvency, 27% on liquidity, 84% on profitability and 34% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,818 companies had the same profile as SOPACHEM has now. Each dot stands for 10 companies, two years later.
95.0%
were still trading
3.7%
stopped another way
1.0%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of SOPACHEM itself: 0.6% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,818 companies, not a prediction for SOPACHEM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €30,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.23 (1.12 in 2024), below the usual 1.5. Short-term debt is 70.5% and cash 12.5% of total assets. 81.6% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 19% of 95 sector peers (2025).
NBB · sector comparisonPosition among 95 sector peers
Solvency
better than 19%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
21 days early
2024
60 days late
2023
99 days late
2022
29 days late
2021
23 days early
2020
19 days early
2019
15 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 16 days after the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 August (4 of the last 5 accounts filed within 52 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- Helys Group 100%equity €2.0m (2025) · 2025 annual accounts of Helys Group
Recent changes
New establishment in Wevelgem
Vlamingstraat 4
Purpose change
“Het verrichten, in het algemeen, van alle roerende, onroerende, commerciële, industriële, financiële…” (deed in Dutch) · General meeting of 20-12-2024 · Gazette deed
Permanent representatives: Danny Pattyn and Kathleen De Kegel
Board meeting of 28-10-2024 · Gazette deed
Registered office moved from Nazareth to Zwevegem
New registered office: Pluim 20 bus A, 8550 ZWEVEGEM · Previous registered office: Nieuwe Steenweg 20 bus A, 9810 NAZARETH · Resignations: Danny PATTYN, APTCO INVEST BV, INNSPIKE BV and INNPULSE BV · General meeting of 30-10-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SOPACHEM Zwevegem | €2.3m | €0.9m | 18.4% | 3.8 |
| MERIDIAN BIOSCIENCE EUROPE Braine-l'Alleud | €0.6m | €0.4m | 72.9% | - |
| GREEN 2 Ostend | €2.0m | €0.1m | 48.6% | 0.2 |
| REPROBIOL Ouffet | €1.9m | €0.5m | 78.0% | 5.8 |
| DIAGAM Ath | €7.3m | €4.0m | 55.2% | 23.9 |
| PHARMACIE DE GIVRY Quévy | €1.3m | €0.5m | 37.4% | 4.4 |
| LIFRANK Wingene | €4.1m | €0.2m | 64.0% | - |
These companies have the same main activity as SOPACHEM: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €618,000 and €7.3m, founded between 1971 and 2008.
Official details
Source: KBO- Status
- Active since 16-04-1970Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21100and 1 other
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment units
- 2.004.096.5118550 Zwevegem, since 01-04-1970
- 2.376.443.6798560 Wevelgem, since 01-07-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 12-10-2023
Annual accounts 2025
- ≈ €2.2mestimated
- €2.3m▼ 19.5%
- Employeeson 31-12-2025
- 5▲ 66.7%
- Filing
- Filed on 10-07-2026, 21 days before the end of the filing period
Insights on SOPACHEM
SOPACHEM has existed since 1970. In 2020 the gross margin rose from €407,926 to €1.1m.
Helys Group holds all the shares. In October 2024, four directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about SOPACHEM
- What is the company number of SOPACHEM?
- The company number of SOPACHEM is 0407.132.457. The VAT number is the same number with BE in front: BE 0407.132.457.
- Where is SOPACHEM based?
- The registered office is at Pluim 20, 8550 Zwevegem.Company details
- What does SOPACHEM do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of SOPACHEM?
- SOPACHEM is a public limited company (NV).
- When was SOPACHEM founded?
- SOPACHEM was founded on 16-04-1970.
- Is SOPACHEM still active?
- Yes, SOPACHEM is an active enterprise in the KBO register.
- How many employees does SOPACHEM have?
- SOPACHEM had an average of 3.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does SOPACHEM fall under?
- In its 2025 annual accounts, SOPACHEM states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of SOPACHEM?
- The turnover in financial year 2025 is ≈ €2.2m. This figure is estimated from the gross margin of €943,412 and 2,275 comparable companies of the same size. It probably lies between €1.3m and €3.8m. It is a rough estimate.
- Is SOPACHEM profitable?
- In financial year 2025, SOPACHEM made a profit of €407,699.
- Where can I find the annual accounts of SOPACHEM?
- SOPACHEM filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SOPACHEM due?
- SOPACHEM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.